UK Markets closed

Cipla Limited (CIPLA.NS)

NSE - NSE Real-time price. Currency in INR
Add to watchlist
867.45-14.90 (-1.69%)
At close: 03:30PM IST
Full screen
Previous close882.35
Open880.00
Bid867.45 x 0
Ask0.00 x 0
Day's range860.00 - 880.00
52-week range738.10 - 1,005.00
Volume1,669,132
Avg. volume2,301,889
Market cap704.507B
Beta (5Y monthly)0.40
PE ratio (TTM)27.06
EPS (TTM)32.05
Earnings date25 Jan 2022
Forward dividend & yield5.00 (0.54%)
Ex-dividend date09 Aug 2021
1y target est1,064.30
  • Reuters

    Eli Lilly signs deals to boost supply of COVID-19 treatment in India

    BENGALURU (Reuters) -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients. The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab. The three Indian drugmakers - Cipla Ltd, Lupin Ltd and Sun Pharma - will collaborate with U.S.-based Lilly to help make and sell baricitinib in India.

  • Reuters

    Cipla doubles remdesivir production to meet 'unprecedented' demand

    India's Cipla Ltd has doubled production of COVID-19 medication remdesivir to help meet "unprecedented demand" as the country battles a massive second wave of infections, the drugmaker said on Tuesday. India has overtaken Brazil as the world's second-worst coronavirus-hit country after the United States, having administered about 107 million vaccine doses among a population of 1.4 billion. On Sunday, the country banned the export of anti-viral drug remdesivir and its active pharmaceutical ingredients to deal with crippling shortages of the medication in many parts.

  • Reuters

    Indian pharma firms go local seeking to end reliance on China

    Indian drug companies are looking to local makers of so-called active pharmaceutical ingredients (API) or trying to make them in-house in a bid to end their reliance on China as ties between the two countries soured after a deadly border clash last June. Though India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounted for half of its API needs in 2019 from nearly nothing three decades ago, industry data shows. Executives at India's Cadila Healthcare, Cipla, Sun Pharmaceutical and ‎Biocon said on Tuesday they were aggressively working on reducing the dependence on the richer rival for raw materials.